Simon Quick Advisors LLC Has $365,000 Position in Astrazeneca Plc $AZN

Simon Quick Advisors LLC trimmed its position in Astrazeneca Plc (NYSE:AZN) by 62.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,851 shares of the company’s stock after selling 3,029 shares during the quarter. Simon Quick Advisors LLC’s holdings in Astrazeneca were worth $365,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. IHT Wealth Management LLC lifted its holdings in shares of Astrazeneca by 0.3% during the fourth quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock worth $3,076,000 after buying an additional 54 shares in the last quarter. Visionary Wealth Advisors grew its stake in shares of Astrazeneca by 1.5% in the fourth quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock valued at $737,000 after acquiring an additional 60 shares in the last quarter. Vista Investment Management grew its stake in shares of Astrazeneca by 0.3% in the fourth quarter. Vista Investment Management now owns 21,215 shares of the company’s stock valued at $3,723,000 after acquiring an additional 60 shares in the last quarter. Kestra Investment Management LLC increased its position in Astrazeneca by 1.9% during the fourth quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after acquiring an additional 63 shares during the period. Finally, Luken Investment Analytics LLC increased its position in Astrazeneca by 4.3% during the fourth quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock worth $274,000 after acquiring an additional 64 shares during the period. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of recent research reports. Bank of America reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Finally, HSBC downgraded Astrazeneca from a “buy” rating to a “hold” rating in a research report on Monday, July 13th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $211.00.

Astrazeneca Price Performance

Shares of NYSE:AZN opened at $168.81 on Monday. The firm has a 50 day moving average of $182.16 and a 200-day moving average of $188.44. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $261.82 billion, a PE ratio of 25.35, a PEG ratio of 1.38 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, equities research analysts predict that Astrazeneca Plc will post 10.22 EPS for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.